ADVERTISEMENT

Correction: Diabetes management

Cleveland Clinic Journal of Medicine. 2019 November;86(11):760

Information was omitted from Table 1 on page 596 of the article, Makin V, Lansang MC. Diabetes management: beyond hemoglobin A1c (Cleve Clin J Med 2019; 86[9]:595–600, doi:10.3949/ccjm.86a.18031).

The sodium-glucose cotransporter 2 (SGLT2) inhibitors pose a low risk of hypoglyemia, and that should have been noted in the table. The corrected table appears below and online.

Table 1. Advantages of selected type 2 diabetes drugs